Neoadjuvant therapy in cancer treatment

Area of Science:

• Oncology
• Cancer Treatment
• Surgical Oncology

Background:

• Neoadjuvant therapy, administered before local treatment (surgery or radiation), is increasingly vital in cancer care.
• Its definition has expanded to encompass radiation therapy preceding surgery.
• Potential benefits include enhanced local/distant control and organ preservation, while drawbacks involve toxicity and cost.

Purpose of the Study:

• To explore the evolving role and categorization of neoadjuvant therapy in cancer treatment.
• To highlight examples of neoadjuvant therapy's success in specific cancers.
• To emphasize the need for rigorous comparison with standard treatments.

Main Methods:

• Review of current neoadjuvant therapy applications and outcomes.
• Examination of neoadjuvant therapy's impact on osteogenic sarcoma, laryngeal cancer, and breast cancer.
• Discussion of criteria for evaluating neoadjuvant therapy efficacy.

Main Results:

• Neoadjuvant therapy is standard for osteogenic sarcoma, enabling limb salvage and tailored chemotherapy.
• In advanced laryngeal cancer, neoadjuvant chemotherapy with radiation allows laryngeal preservation.
• Promising results are emerging for neoadjuvant chemotherapy in breast cancer, with ongoing comparative trials.

Conclusions:

• Neoadjuvant therapy is categorized by proven efficacy, organ-sparing potential, or unproven utility.
• Successful examples demonstrate its value in specific oncological settings.
• Further comparative studies are crucial to assess recurrence, survival, organ sparing, quality of life, and costs against standard therapies.